European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 17 February 2026 - 17:00

Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 17 February 2026 - 16:52

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 12, Status: Authorised

ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 29 October 2025, 09:30 (CET) to 29 October 2025, 17:00 (CET)

Submitted by Anonymous (not verified) on 17 February 2026 - 16:00

ACT EU multi-stakeholder platform annual meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 29 October 2025, 09:30 (CET) to 29 October 2025, 17:00 (CET)

Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 34, Status: Authorised

Submitted by Anonymous (not verified) on 17 February 2026 - 12:49

Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 17 February 2026 - 11:55

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Arexvy, recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E, Date of authorisation: 06/06/2023, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 17 February 2026 - 10:58

Human medicines European public assessment report (EPAR): Arexvy, recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E, Date of authorisation: 06/06/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Bronchitol, mannitol, Date of authorisation: 13/04/2012, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 17 February 2026 - 10:20

Human medicines European public assessment report (EPAR): Bronchitol, mannitol, Date of authorisation: 13/04/2012, Revision: 20, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More